|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Vizcaino AP, Moreno V, Lambert R and
Parkin DM: Time trends incidence of both major histologic types of
esophageal carcinomas in selected countries, 1973–1995. Int J
Cancer. 99:860–868. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Layke JC and Lopez PP: Esophageal cancer:
a review and update. Am Fam Physician. 73:2187–2194.
2006.PubMed/NCBI
|
|
5
|
Stoner GD and Wang LS: Chemoprevention of
esophageal squamous cell carcinoma with berries. Top Curr Chem.
329:1–20. 2013. View Article : Google Scholar
|
|
6
|
Kamangar F, Chow WH, Abnet CC and Dawsey
SM: Environmental causes of esophageal cancer. Gastroenterol Clin
North Am. 38:27–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hyland PL, Freedman ND, Hu N, Tang ZZ,
Wang L, Wang C, Ding T, Fan JH, Qiao YL, Golozar A, et al: Genetic
variants in sex hormone metabolic pathway genes and risk of
esophageal squamous cell carcinoma. Carcinogenesis. 34:1062–1068.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF,
Huang Q, Fang GQ and Li EM: MiRNA profile in esophageal squamous
cell carcinoma: downregulation of miR-143 and miR-145. World J
Gastroenterol. 17:79–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuchiya S, Fujiwara T, Sato F, Shimada Y,
Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210
regulates cancer cell proliferation through targeting fibroblast
growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428.
2011. View Article : Google Scholar :
|
|
13
|
Kong KL, Kwong DL, Chan TH, Law SY, Chen
L, Li Y, Qin YR and Guan XY: MicroRNA-375 inhibits tumour growth
and metastasis in oesophageal squamous cell carcinoma through
repressing insulin-like growth factor 1 receptor. Gut. 61:33–42.
2012. View Article : Google Scholar
|
|
14
|
Kang M, Li Y, Liu W, Wang R, Tang A, Hao
H, Liu Z and Ou H: miR-129-2 suppresses proliferation and migration
of esophageal carcinoma cells through downregulation of SOX4
expression. Int J Mol Med. 32:51–58. 2013.PubMed/NCBI
|
|
15
|
Wang N, Zhang CQ, He JH, Duan XF, Wang YY,
Ji X, Zang WQ, Li M, Ma YY, Wang T and Zhao GQ: MiR-21
down-regulation suppresses cell growth, invasion and induces cell
apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal
carcinoma. Dig Dis Sci. 58:1863–1870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ni Y, Meng L, Wang L, Dong W, Shen H, Wang
G, Liu Q and Du J: MicroRNA-143 functions as a tumor suppressor in
human esophageal squamous cell carcinoma. Gene. 517:197–204. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang M, Zhou S, Zhang L, Zhang J, Cai H,
Zhu J, Huang C and Wang J: miR-518b is down-regulated, and involved
in cell proliferation and invasion by targeting Rap1b in esophageal
squamous cell carcinoma. FEBS Lett. 586:3508–3521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
19
|
Ding DP, Chen ZL, Zhao XH, Wang JW, Sun J,
Wang Z, Tan FW, Tan XG, Li BZ, Zhou F, et al: miR-29c induces cell
cycle arrest in esophageal squamous cell carcinoma by modulating
cyclin E expression. Carcinogenesis. 32:1025–1032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu HL, Wu P, Wang XF, Wang JG, Jiao F,
Song LL, Xie H, Wen XY, Shan HS, Du YX and Zhao YP: Altered miRNA
expression is associated with differentiation, invasion, and
metastasis of esophageal squamous cell carcinoma (ESCC) in patients
from Huaian, China. Cell Biochem Biophys. 67:657–668. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Novello C, Pazzaglia L, Cingolani C, Conti
A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA
expression profile in human osteosarcoma: role of miR-1 and
miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013.
|
|
22
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21.
2012.PubMed/NCBI
|
|
23
|
Hou G, Zhang Q, Wang L, Liu M, Wang J and
Xue L: mTOR inhibitor rapamycin alone or combined with cisplatin
inhibits growth of esophageal squamous cell carcinoma in nude mice.
Cancer Lett. 290:248–254. 2010. View Article : Google Scholar
|
|
24
|
Wang F, Zhang P, Ma Y, Yang J, Moyer MP,
Shi C, Peng J and Qin H: NIRF is frequently upregulated in
colorectal cancer and its oncogenicity can be suppressed by let-7a
microRNA. Cancer Lett. 314:223–231. 2012. View Article : Google Scholar
|
|
25
|
Matsushima K, Isomoto H, Yamaguchi N,
Inoue N, Machida H, Nakayama T, Hayashi T, Kunizaki M, Hidaka S,
Nagayasu T, et al: MiRNA-205 modulates cellular invasion and
migration via regulating zinc finger E-box binding homeobox 2
expression in esophageal squamous cell carcinoma cells. J Transl
Med. 9:302011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leidner RS, Ravi L, Leahy P, Chen Y,
Bednarchik B, Streppel M, Canto M, Wang JS, Maitra A, Willis J, et
al: The microRNAs, MiR-31 and MiR-375, as candidate markers in
Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer.
51:473–479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH,
Lin JT, Chen YL and Lu PJ: MicroRNA-373 (miR-373)
post-transcriptionally regulates large tumor suppressor, homolog 2
(LATS2) and stimulates proliferation in human esophageal cancer.
Exp Cell Res. 315:2529–2538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar
|
|
30
|
Takeshita N, Mori M, Kano M, Hoshino I,
Akutsu Y, Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, et
al: miR-203 inhibits the migration and invasion of esophageal
squamous cell carcinoma by regulating LASP1. Int J Oncol.
41:1653–1661. 2012.PubMed/NCBI
|
|
31
|
Yamamoto N, Kinoshita T, Nohata N, Itesako
T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor
suppressive microRNA-218 inhibits cancer cell migration and
invasion by targeting focal adhesion pathways in cervical squamous
cell carcinoma. Int J Oncol. 42:1523–1532. 2013.PubMed/NCBI
|
|
32
|
Leone V, D'Angelo D, Rubio I, de Freitas
PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco
A: MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting
CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab.
96:E1388–E1398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li D, Yang P, Li H, Cheng P, Zhang L, Wei
D, Su X, Peng J, Gao H, Tan Y, et al: MicroRNA-1 inhibits
proliferation of hepatocarcinoma cells by targeting endothelin-1.
Life Sci. 91:440–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu YN, Yin JJ, Abou-Kheir W, Hynes PG,
Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, et
al: MiR-1 and miR-200 inhibit EMT via Slug-dependent and
tumorigenesis via Slug-independent mechanisms. Oncogene.
32:296–306. 2013. View Article : Google Scholar
|
|
35
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in
head and neck squamous cell carcinoma. Oncotarget. 2:29–42.
2011.PubMed/NCBI
|
|
36
|
Taulli R, Bersani F, Foglizzo V, Linari A,
Vigna E, Ladanyi M, Tuschl T and Ponzetto C: The muscle-specific
microRNA miR-206 blocks human rhabdomyosarcoma growth in
xenotransplanted mice by promoting myogenic differentiation. J Clin
Invest. 119:2366–2378. 2009.PubMed/NCBI
|
|
37
|
Wu CD, Kuo YS, Wu HC and Lin CT:
MicroRNA-1 induces apoptosis by targeting prothymosin alpha in
nasopharyngeal carcinoma cells. J Biomed Sci. 18:802011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Tumour suppressive microRNA-874 regulates novel
cancer networks in maxillary sinus squamous cell carcinoma. Br J
Cancer. 105:833–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Sasaki K, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Identification of novel molecular targets
regulated by tumor suppressive miR-1/miR-133a in maxillary sinus
squamous cell carcinoma. Int J Oncol. 39:1099–1107. 2011.PubMed/NCBI
|
|
40
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and
Seki N: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar :
|
|
41
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kato H, Arao T, Matsumoto K, Fujita Y,
Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, et
al: Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal
squamous cell carcinoma. Int J Oncol. 42:1151–1158. 2013.PubMed/NCBI
|
|
43
|
Grugan KD, Miller CG, Yao Y, Michaylira
CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han M, Nakagawa
H and Rustgi AK: Fibroblast-secreted hepatocyte growth factor plays
a functional role in esophageal squamous cell carcinoma invasion.
Proc Natl Acad Sci USA. 107:11026–11031. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Leelawat K, Leelawat S, Tepaksorn P,
Rattanasinganchan P, Leungchaweng A, Tohtong R and Sobhon P:
Involvement of c-Met/hepatocyte growth factor pathway in
cholangiocarcinoma cell invasion and its therapeutic inhibition
with small interfering RNA specific for c-Met. J Surg Res.
136:78–84. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ketterer K, Kong B, Frank D, Giese NA,
Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW and Friess H:
Neuromedin U is overexpressed in pancreatic cancer and increases
invasiveness via the hepatocyte growth factor c-Met pathway. Cancer
Lett. 277:72–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan
SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT IV, et
al: c-Met gene amplification is associated with advanced stage
colorectal cancer and liver metastases. Cancer Lett. 265:258–269.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu
MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, et al: Role of overexpression of
CD151 and/or c-Met in predicting prognosis of hepatocellular
carcinoma. Hepatology. 49:491–503. 2009. View Article : Google Scholar
|
|
48
|
Drebber U, Baldus SE, Nolden B, Grass G,
Bollschweiler E, Dienes HP, Hölscher AH and Mönig SP: The
overexpression of c-met as a prognostic indicator for gastric
carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep.
19:1477–1483. 2008.PubMed/NCBI
|
|
49
|
Tuynman JBLS, Lagarde SM, Ten Kate FJ,
Richel DJ and van Lanschot JJ: Met expression is an independent
prognostic risk factor in patients with oesophageal adenocarcinoma.
Br J Cancer. 98:1102–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cecchi F, Rabe DC and Bottaro DP:
Targeting the HGF/Met signaling pathway in cancer therapy. Expert
Opin Ther Targets. 16:553–572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Peters S and Adjei AA: MET: A promising
anticancer therapeutic target. Nat Rev Clin Oncol. 9:314–326. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Reid JF, Sokolova V, Zoni E, Lampis A,
Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino
G, et al: miRNA profiling in colorectal cancer highlights miR-1
involvement in MET-dependent proliferation. Mol Cancer Res.
10:504–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yan D, Dong XE, Chen X, Wang L, Lu C, Wang
J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits
rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shirali S, Aghaei M, Shabani M, Fathi M,
Sohrabi M and Moeinifard M: Adenosine induces cell cycle arrest and
apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian
cancer cell line OVCAR-3. Tumour Biol. 34:1085–1095. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fong LY, Nguyen VT, Farber JL, Huebner K
and Magee PN: Early deregulation of the the p16ink4a-cyclin
D1/cyclin-dependent kinase 4-retinoblastoma pathway in cell
proliferation-driven esophageal tumorigenesis in zinc-deficient
rats. Cancer Res. 60:4589–4595. 2000.PubMed/NCBI
|
